Lupin aims for Japan top five, converting generics and offering Indian firms a way in
This article was originally published in Scrip
India's Lupin expects to be among the top five to six generic companies in Japan by 2015, backed by a multi-faceted strategy that will include product introductions, shifting production to India to improve profitability, and an interest in brand buys, among others. Currently Lupin's Japanese subsidiary, Kyowa Pharmaceutical Industry Co, is the ninth largest generic pharmaceutical firm in Japan.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.